

AmerisourceBergen Reports Earnings Per Share Up 48 Percent to \$0.86 Before Special Charges in June Quarter

July 31, 2002

Synergy Capture and Low Interest Expense Continue to Drive Results

VALLEY FORGE, Pa., Jul 31, 2002 (BUSINESS WIRE) -- AmerisourceBergen Corporation (NYSE:ABC) today reported results for its fiscal third quarter and nine months ended June 30, 2002. AmeriSource Health Corporation and Bergen Brunswig Corporation merged on August 29, 2001 to form AmerisourceBergen Corporation. Under purchase accounting rules, AmerisourceBergen's fiscal 2002 third quarter and nine-month results are compared with the fiscal 2001 third quarter and nine-month results of AmeriSource only. Pro forma data included in this discussion refers to the combined predecessor companies' operating results in the previous year's third quarter and first nine months, adjusted to eliminate amortization of goodwill. Both former companies had the same fiscal year ending September 30.

Diluted earnings per share before special charges for the third quarter of fiscal 2002 were \$0.86, a 48 percent increase over the previous year's third quarter. Income before special charges for the third quarter of fiscal 2002 increased to \$95.1 million from \$32.1 million in the same period last year. Special charges, consisting of merger integration costs, were \$4.9 million, net of tax, in the quarter. Net income and diluted earnings per share for the quarter were \$90.2 million and \$0.82, respectively.

AmerisourceBergen's operating revenue, which excludes bulk deliveries to customer warehouses, was \$10.3 billion in the third quarter of fiscal 2002 compared to \$3.5 billion for the same period last year. Fiscal 2002 third quarter operating revenue increased 14 percent over fiscal 2001 third quarter pro forma operating revenue of \$9.0 billion.

For the first nine months of fiscal 2002, diluted earnings per share before special charges were \$2.41, a 46 percent increase over the prior year. Special charges, consisting of merger integration costs, were \$12.3 million, net of tax, in the first nine months of fiscal 2002. Operating revenue for the nine-month period ended June 30, 2002 was \$29.9 billion compared to \$10.3 billion in the prior year, and represents a 17 percent increase over pro forma operating revenue of \$25.5 billion in the first nine months of fiscal 2001. Net income and diluted earnings per share for the nine-month period ended June 30, 2002 were \$250.0 million and \$2.30, respectively.

For the third quarter of fiscal 2002, interest expense, including pretax distributions on preferred securities of a subsidiary trust, was \$33.3 million, reflecting disciplined asset management and a favorable interest rate environment.

The following discussion of results, including segment data, does not include the impact of the special charges in the third quarter and first nine months of fiscal 2002.

"This was another exceptional performance by AmerisourceBergen, demonstrating our continuing ability to leverage the cost saving and scale synergies of our new company," said R. David Yost, AmerisourceBergen President and Chief Executive Officer. "We continued to capture synergy cost savings from the merger earlier than expected, and new scale synergies are improving contributions from pharmaceutical purchasing. Strong working capital management and a historically low interest rate environment also positively impacted the Company's performance. All these factors drove excellent earnings per share growth, operating margin expansion and a very strong return on committed capital (ROCC) of 24.6 percent.

"During the quarter we announced and this month completed the \$120 million acquisition of AutoMed Technologies, Inc. This acquisition, which is expected to be slightly accretive to earnings, enhances our position in the pharmaceutical supply chain by providing our retail and institutional customers with a pharmacy automation solution that reduces the cost of drug dispensing, improves dispensing accuracy and addresses staffing pressures."

Segment Discussion

AmerisourceBergen operates in two segments: Pharmaceutical Distribution (which includes the AmerisourceBergen Drug Company and AmerisourceBergen Specialty Group operations) and PharMerica (which includes the institutional pharmacy and workers' compensation fulfillment businesses). Intersegment sales of \$189.7 million in the third quarter of fiscal 2002 from AmerisourceBergen Drug Company to PharMerica, which are included in the Pharmaceutical Distribution segment operating revenue, are eliminated for consolidated reporting purposes.

Pharmaceutical Distribution Segment

Operating revenue in the third quarter of fiscal 2002 increased to \$10.1 billion compared with \$3.5 billion in the previous year's third quarter. Operating revenue increased 14 percent over fiscal 2001 third quarter pro forma revenue of \$8.8 billion.

Pharmaceutical Distribution customer mix in the third quarter of fiscal 2002 was 52 percent institutional and 48 percent retail. AmerisourceBergen is the market leader in pharmaceutical distribution to hospital systems and acute care facilities, alternate care facilities, independent community pharmacies, and regional chain store pharmacies.

Operating income was \$169.1 million in the third quarter of fiscal 2002, up from \$61.1 million for the same quarter last year, and improved 14 percent compared to pro forma operating income of \$147.8 million in the same period last year. For the fiscal 2002 third quarter, operating income, as a percentage of operating revenue, was 1.68 percent, a slight improvement from the prior year's third quarter on a pro forma basis. Lower gross margins, which reflect the Company's customer mix and the competitive environment, were more than offset by lower total operating expenses as a

percentage of operating revenue.

Total operating expenses as a percentage of operating revenue in the fiscal 2002 third quarter were 2.15 percent, a 24 basis point improvement over the same quarter last year on a pro forma basis driven by synergy cost savings, customer mix and operating leverage.

AmerisourceBergen Specialty Group, with annualized revenue well over \$2.5 billion, had another very strong quarter, building significant positions in oncology, blood plasma and vaccine distribution as well as growing its manufacturing services businesses.

"The momentum from our integration activities continues to build. Distribution center consolidations are on schedule and going smoothly. Last week we successfully completed the consolidation of our Portland, Oregon distribution center into our Seattle facility. Three additional distribution centers are scheduled for consolidation by the end of September, bringing the total number of consolidations in the fiscal year to seven, in line with the goal we set at the beginning of the year," said Kurt J. Hilzinger, AmerisourceBergen Executive Vice President and Chief Operating Officer. "We also continue to leverage our larger scale as our new generic pharmaceutical program gained traction in the marketplace and our common employee benefits plan was rolled out July 1, 2002. Our recently combined sales force hosted the highly successful first annual AmerisourceBergen Healthcare Conference for customers, establishing the largest such event in the industry with over 6,000 people in attendance."

PharMerica

PharMerica's operating revenue for the third quarter of fiscal 2002 was \$373.8 million, representing an 11 percent increase over pro forma operating revenue of \$336.8 million in the same period last year.

Operating income for the third quarter of fiscal 2002 was \$21.8 million, a 28 percent increase over the prior year's pro forma third quarter operating income of \$17.0 million.

Operating income as a percentage of operating revenue increased 79 basis points in the quarter ended June 30, 2002 to 5.82 percent from 5.03 percent on a pro forma basis in the prior year.

"Double-digit revenue growth reflected continued strong performance by PharMerica's workers compensation business, as well as improved growth in the long-term care business," said Hilzinger. "Cost savings from expense control, driven by the favorable effect of a single information technology platform and continued accounts receivables discipline, as well as the positive impact of the new generic drug program, enhanced PharMerica's performance in the quarter."

Looking Ahead

"We expect continued strong performance for AmerisourceBergen for the fiscal 2002 fourth quarter with diluted earnings per share excluding special charges in the range of \$0.83 to \$0.85, ROCC in excess of our 20 percent target, and revenue growth consistent with the third quarter fiscal 2002 performance," said Yost. "We are increasing our diluted earnings per share estimate for fiscal year 2002, excluding the impact of merger-related special charges, from \$3.15 to a range of \$3.24 to \$3.26, the third estimate increase this fiscal year. The increase in earnings expectations for the year reflects the solid performance of our businesses in the third quarter, early capture of cost saving synergies, and continued low interest rates. We remain confident in our ability to achieve annual cost saving synergies of \$150 million by the end of fiscal year 2004."

Also, in response to the recent order of the Security and Exchange Commission seeking sworn statements from the principal executive officers and principal financial officers of large public companies, Yost and Senior Vice President and Chief Financial Officer Michael D. DiCandilo each will file certifications by the August 14, 2002 deadline affirming that AmerisourceBergen's 10-K Report for fiscal 2001, 10-Q Reports for fiscal 2002, and 2002 Annual Meeting proxy statement were materially complete and truthful."

Conference Call

The Company will host a conference call to discuss the results at 11:00 a.m. Eastern Daylight Time on July 31, 2002. Participating in the conference call will be: R. David Yost, President & Chief Executive Officer; Kurt J. Hilzinger, Executive Vice President & Chief Operating Officer; and Michael D. DiCandilo, Senior Vice President & Chief Financial Officer.

To access the live conference call via telephone:

Dial in:

800-553-5260 from inside the U.S. no access code required
or 612-332-1210 from outside the U.S. no access code required.

To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at <http://www.amerisourcebergen.net>.

A replay of the telephone call and webcast will be available from 4:15 p.m. July 31, 2002 until 11:59 p.m. August 7, 2002.

To access the replay via telephone:

Dial in:

800-475-6701 from within the U.S., access code: 643950
320-365-3844 from outside the U.S., access code: 643950

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at <http://www.amerisourcebergen.net>.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is the largest pharmaceutical services company in the United States dedicated solely to the pharmaceutical supply chain. It is the leading distributor of pharmaceutical products and services to the hospital systems and acute care market, alternate care facilities, independent community pharmacies, and regional chain pharmacies. The Company is also a leader in the institutional pharmacy marketplace. With more than \$40 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people serving over 25,000 customers.

Forward-Looking Statements

This press release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements herein include statements addressing future financial and operating results of AmerisourceBergen and the benefits and other aspects of the merger between Amerisource Health Corporation and Bergen Brunswig Corporation.

The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the risk that the businesses of AmeriSource and Bergen Brunswig will not be integrated successfully; failure to obtain and retain expected synergies; and other economic, business, competitive and/or regulatory factors affecting the business of AmerisourceBergen generally.

More detailed information about these factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2001, its Quarterly Reports on Form 10-Q for the first and second quarters of fiscal 2002, and the joint proxy statement-prospectus for the merger as filed on August 1, 2001.

AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward-looking statements whether as a result of new information, future events or otherwise.

AMERISOURCEBERGEN CORPORATION FINANCIAL SUMMARY

(In thousands, except per share data)

(unaudited)

| Three Months Ended June 30, 2002 | Three Months Ended June 30, 2001 | % of Operating Revenue | Three Months Ended June 30, 2001 | % of Operating Revenue | % Change |
|--|--|------------------------------|--|------------------------------|-------------|
|--|--|------------------------------|--|------------------------------|-------------|

Revenue:

| | | | | | |
|-------------------|--------------|---------|-------------|---------|------|
| Operating revenue | \$10,278,327 | 100.00% | \$3,518,852 | 100.00% | 192% |
|-------------------|--------------|---------|-------------|---------|------|

| | | | | | |
|--|-----------|--|----|----|--|
| Bulk deliveries to customer warehouses | 1,342,500 | | 77 | -- | |
|--|-----------|--|----|----|--|

| | | | | | |
|---------------|------------|--|-----------|------|--|
| Total revenue | 11,620,827 | | 3,518,929 | 230% | |
|---------------|------------|--|-----------|------|--|

| | | | | | |
|--------------------|------------|--|-----------|------|--|
| Cost of goods sold | 11,110,898 | | 3,373,990 | 229% | |
|--------------------|------------|--|-----------|------|--|

| | | | | | |
|--------------|---------|-------|---------|-------|------|
| Gross profit | 509,929 | 4.96% | 144,939 | 4.12% | 252% |
|--------------|---------|-------|---------|-------|------|

Operating expenses:

| | | | | | |
|--|---------|-------|--------|-------|------|
| Distribution, selling and administrative | 304,299 | 2.96% | 79,638 | 2.26% | 282% |
|--|---------|-------|--------|-------|------|

| | | | | | |
|----------------------------------|--------|-------|-------|-------|------|
| Depreciation and amortization | 14,740 | 0.14% | 4,205 | 0.12% | 251% |
|----------------------------------|--------|-------|-------|-------|------|

| | | | | | |
|--------------|-------|-------|-----|-------|----|
| Merger costs | 8,147 | 0.08% | 903 | 0.03% | -- |
|--------------|-------|-------|-----|-------|----|

| | | | | | |
|------------------|---------|-------|--------|-------|------|
| Operating income | 182,743 | 1.78% | 60,193 | 1.71% | 204% |
|------------------|---------|-------|--------|-------|------|

Equity in (income)

| | | | | | |
|--------------------------------------|-------|-------|-------|-------|-------|
| losses of affiliates and other | (190) | 0.00% | 2,006 | 0.06% | -109% |
|--------------------------------------|-------|-------|-------|-------|-------|

| | | | | | |
|------------------|--------|-------|-------|-------|------|
| Interest expense | 27,308 | 0.27% | 7,361 | 0.21% | 271% |
|------------------|--------|-------|-------|-------|------|

Income before taxes
and distributions
on preferred

| | | | | | |
|--------------------------------|---------|-------|--------|-------|------|
| securities of subsidiary trust | 155,625 | 1.51% | 50,826 | 1.44% | 206% |
| Income taxes | 61,771 | 0.60% | 19,320 | 0.55% | 220% |

| | | | | | |
|---|--------|-------|--------|-------|------|
| Income before distributions on preferred securities of subsidiary trust | 93,854 | 0.91% | 31,506 | 0.90% | 198% |
|---|--------|-------|--------|-------|------|

| | | | | | | |
|---|---------|-------|-------|----|-------|----|
| Distributions on preferred securities of subsidiary trust, net of income tax benefit of | \$2,388 | 3,630 | 0.04% | -- | 0.00% | -- |
|---|---------|-------|-------|----|-------|----|

| | | | | | |
|------------|-----------|-------|-----------|-------|------|
| Net income | \$ 90,224 | 0.88% | \$ 31,506 | 0.90% | 186% |
|------------|-----------|-------|-----------|-------|------|

| | | | | | |
|---------------------|---------|----|------|--|--|
| Earnings per share: | | | | | |
| Basic | \$ 0.86 | \$ | 0.60 | | |
| Diluted | \$ 0.82 | \$ | 0.57 | | |

| | | | | | |
|---|---------|--------|--|--|--|
| Weighted average common shares outstanding: | | | | | |
| Basic | 105,374 | 52,912 | | | |
| Diluted | 112,891 | 59,578 | | | |

Pro forma results excluding merger costs in the three months ended June 30, 2002 and 2001:

| | | | |
|------------------|------------|----|--------|
| Operating income | \$ 190,890 | \$ | 61,096 |
| Net income | \$ 95,136 | \$ | 32,066 |

| | | | | | |
|---------------------|---------|----|------|--|--|
| Earnings per share: | | | | | |
| Basic | \$ 0.90 | \$ | 0.61 | | |
| Diluted | \$ 0.86 | \$ | 0.58 | | |

AMERISOURCEBERGEN CORPORATION
FINANCIAL SUMMARY

(In thousands, except per share data)
(unaudited)

| | | | | | |
|---------|-----------|---------|-----------|--------|--|
| | Nine | | Nine | | |
| | Months | | Months | | |
| Ended | % of | Ended | % of | | |
| June 30 | Operating | June 30 | Operating | % | |
| 2002 | Revenue | 2001 | Revenue | Change | |

| | | | | | |
|-------------------|--------------|---------|--------------|---------|------|
| Revenue: | | | | | |
| Operating revenue | \$29,883,212 | 100.00% | \$10,306,288 | 100.00% | 190% |

| | | | | | |
|--|-----------|-----|----|--|--|
| Bulk deliveries to customer warehouses | 3,750,662 | 834 | -- | | |
|--|-----------|-----|----|--|--|

| | | | | | |
|---------------|------------|------------|------|--|--|
| Total revenue | 33,633,874 | 10,307,122 | 226% | | |
|---------------|------------|------------|------|--|--|

| | | | | | |
|--------------------|------------|-----------|------|--|--|
| Cost of goods sold | 32,138,019 | 9,873,581 | 225% | | |
|--------------------|------------|-----------|------|--|--|

| | | | | | |
|--------------|-----------|-------|---------|-------|------|
| Gross profit | 1,495,855 | 5.01% | 433,541 | 4.21% | 245% |
|--------------|-----------|-------|---------|-------|------|

| | | | | | |
|--|---------|-------|---------|-------|------|
| Operating expenses: | | | | | |
| Distribution, selling and administrative | 906,467 | 3.03% | 241,745 | 2.35% | 275% |

| | | | | | |
|-------------------------------|--------|-------|--------|-------|------|
| Depreciation and amortization | 44,189 | 0.15% | 12,380 | 0.12% | 257% |
|-------------------------------|--------|-------|--------|-------|------|

| | | | | | |
|--------------|--------|-------|-----|-------|----|
| Merger costs | 20,385 | 0.07% | 903 | 0.01% | -- |
|--------------|--------|-------|-----|-------|----|

| | | | | | |
|--|---------|-------|---------|-------|------|
| Operating income | 524,814 | 1.76% | 178,513 | 1.73% | 194% |
| Equity in losses of affiliates and other | 1,187 | 0.00% | 4,581 | 0.04% | -74% |
| Interest expense | 91,017 | 0.30% | 30,030 | 0.29% | 203% |

| | | | | | |
|--|---------|-------|---------|-------|------|
| Income before taxes and distributions on preferred securities of subsidiary trust | 432,610 | 1.45% | 143,902 | 1.40% | 201% |
| Income taxes | 171,740 | 0.57% | 54,689 | 0.53% | 214% |

| | | | | | |
|--|---------|-------|--------|-------|------|
| Income before distributions on preferred securities of subsidiary trust | 260,870 | 0.87% | 89,213 | 0.87% | 192% |
|--|---------|-------|--------|-------|------|

| | | | | | |
|--|--------|-------|----|-------|----|
| Distributions on preferred securities of subsidiary trust, net of income tax benefit of \$7,165 | 10,889 | 0.04% | -- | 0.00% | -- |
|--|--------|-------|----|-------|----|

| | | | | | |
|------------|------------|-------|-----------|-------|------|
| Net income | \$ 249,981 | 0.84% | \$ 89,213 | 0.87% | 180% |
|------------|------------|-------|-----------|-------|------|

Earnings per share:

| | | |
|---------|---------|---------|
| Basic | \$ 2.39 | \$ 1.69 |
| Diluted | \$ 2.30 | \$ 1.64 |

Weighted average
common shares
outstanding:

| | | |
|---------|---------|--------|
| Basic | 104,505 | 52,656 |
| Diluted | 111,926 | 57,819 |

Pro forma results excluding merger costs in the nine months ended
June 30, 2002 and 2001:

| | | |
|------------------|------------|------------|
| Operating income | \$ 545,199 | \$ 179,416 |
| Net income | \$ 262,273 | \$ 89,773 |

Earnings per share:

| | | |
|---------|---------|---------|
| Basic | \$ 2.51 | \$ 1.70 |
| Diluted | \$ 2.41 | \$ 1.65 |

AMERISOURCEBERGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(dollars in thousands)

| | | | |
|--------|-------------|---------------|--------|
| ASSETS | (Unaudited) | | |
| | June 30 | September 30, | \$ |
| | 2002 | 2001 | Change |

Current assets:

| | | | |
|--------------------------------|------------|------------|-----------|
| Cash and cash equivalents | \$ 363,406 | \$ 297,626 | \$ 65,780 |
| Accounts receivable, net | 2,131,273 | 2,142,663 | (11,390) |
| Merchandise inventories | 5,174,024 | 5,056,257 | 117,767 |
| Prepaid expenses and | | | |

| | | | |
|----------------------|--------------|--------------|------------|
| other | 18,793 | 15,956 | 2,837 |
| ----- | | | |
| Total current assets | 7,687,496 | 7,512,502 | 174,994 |
| Long-term assets | 2,745,198 | 2,778,743 | (33,545) |
| ----- | | | |
| Total assets | \$10,432,694 | \$10,291,245 | \$ 141,449 |
| ===== | | | |

LIABILITIES AND STOCKHOLDERS' EQUITY

| | | | |
|---|--------------|--------------|--------------|
| Current liabilities: | | | |
| Accounts payable | \$ 4,764,316 | \$ 4,991,884 | (\$ 227,568) |
| Current portion of long-term debt | 45,000 | 2,468 | 42,532 |
| Other current liabilities | 633,998 | 538,101 | 95,897 |
| ----- | | | |
| Total current liabilities | 5,443,314 | 5,532,453 | (89,139) |
| Long-term debt, less current portion | 1,493,511 | 1,597,295 | (103,784) |
| Other liabilities | 30,678 | 48,317 | (17,639) |
| Company-obligated mandatorily redeemable preferred securities of subsidiary trust | 275,120 | 274,616 | 504 |
| Stockholders' equity | 3,190,071 | 2,838,564 | 351,507 |
| ----- | | | |
| Total liabilities and stockholders' equity | \$10,432,694 | \$10,291,245 | \$ 141,449 |
| ===== | | | |

AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION

(dollars in thousands)

Three Months Ended June 30,

| | Actual 2002 | Actual 2001 | Pro forma 2001 (1) | Actual % Change | Pro forma % Change |
|-------------------|--------------|-------------|--------------------|-----------------|--------------------|
| Operating Revenue | | | | | |
| Pharmaceutical | | | | | |
| Distribution | \$10,094,205 | \$3,518,852 | \$8,835,163 | 187% | 14% |
| PharMerica | 373,791 | -- | 336,783 | -- | 11% |
| Intersegment | | | | | |
| Eliminations | (189,669) | -- | (176,831) | -- | 7% |
| ----- | | | | | |

| | | | | | |
|-------------------|--------------|-------------|-------------|------|-----|
| Operating revenue | \$10,278,327 | \$3,518,852 | \$8,995,115 | 192% | 14% |
|-------------------|--------------|-------------|-------------|------|-----|

Three Months Ended June 30,

| | Actual 2002 | Actual 2001 | Pro forma 2001 (1) | Actual % Change | Pro forma % Change |
|----------------------|-------------|-------------|--------------------|-----------------|--------------------|
| Operating Income (2) | | | | | |

| | | | | | |
|----------------|-----------|----------|-----------|------|-----|
| ----- | | | | | |
| Pharmaceutical | | | | | |
| Distribution | \$169,134 | \$61,096 | \$147,826 | 177% | 14% |
| PharMerica | 21,756 | -- | 16,956 | -- | 28% |
| ----- | | | | | |

| | | | | | |
|------------------|-----------|----------|-----------|------|-----|
| Operating income | \$190,890 | \$61,096 | \$164,782 | 212% | 16% |
| ===== | | | | | |

Percentages of operating revenue (2):

Pharmaceutical

| | | | |
|--------------------|-------|-------|-------|
| Distribution | | | |
| Gross profit | 3.83% | 4.12% | 4.06% |
| Operating expenses | 2.15% | 2.38% | 2.39% |
| Operating income | 1.68% | 1.74% | 1.67% |

PharMerica

| | | | |
|--------------------|--------|----|--------|
| Gross profit | 33.11% | -- | 34.80% |
| Operating expenses | 27.29% | -- | 29.76% |
| Operating income | 5.82% | -- | 5.03% |

AmerisourceBergen

Corporation

| | | | |
|--------------------|-------|-------|-------|
| Gross profit | 4.96% | 4.12% | 5.29% |
| Operating expenses | 3.10% | 2.38% | 3.46% |
| Operating income | 1.86% | 1.74% | 1.83% |

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes merger costs.

AMERISOURCEBERGEN CORPORATION
SUMMARY SEGMENT INFORMATION
(dollars in thousands)
Nine Months Ended June 30,

| | | | | | |
|-------------------|-------------|-------------|--------------------|-----------------|--------------------|
| ----- | | | | | |
| Pro | | | | | |
| Operating Revenue | Actual 2002 | Actual 2001 | Pro forma 2001 (1) | Actual % Change | Pro forma % Change |
| ----- | | | | | |

Pharmaceutical

| | | | | | |
|--------------|--------------|--------------|--------------|------|-----|
| Distribution | \$29,367,184 | \$10,306,288 | \$25,100,466 | 185% | 17% |
| PharMerica | 1,088,967 | -- | 1,011,873 | -- | 8% |
| Intersegment | | | | | |
| Eliminations | (572,939) | -- | (565,713) | -- | 1% |
| ----- | | | | | |

| | | | | | |
|-------------------|--------------|--------------|--------------|------|-----|
| Operating revenue | \$29,883,212 | \$10,306,288 | \$25,546,626 | 190% | 17% |
| ===== | | | | | |

Nine Months Ended June 30,

| | | | | | |
|----------------------|-------------|-------------|--------------------|-----------------|--------------------|
| ----- | | | | | |
| Operating Income (2) | Actual 2002 | Actual 2001 | Pro forma 2001 (1) | Actual % Change | Pro forma % Change |
| ----- | | | | | |

Pharmaceutical

| | | | | | |
|--------------|-----------|-----------|-----------|------|-----|
| Distribution | \$484,586 | \$179,416 | \$408,630 | 170% | 19% |
| PharMerica | 60,613 | -- | 50,177 | -- | 21% |
| ----- | | | | | |

| | | | | | |
|------------------|-----------|-----------|-----------|------|-----|
| Operating income | \$545,199 | \$179,416 | \$458,807 | 204% | 19% |
| ===== | | | | | |

Percentages of operating revenue (2):

Pharmaceutical

| | | | | |
|--------------------|-------|-------|-------|--|
| Distribution | | | | |
| Gross profit | 3.85% | 4.21% | 4.14% | |
| Operating expenses | 2.20% | 2.47% | 2.51% | |
| Operating income | 1.65% | 1.74% | 1.63% | |

PharMerica

| | | | | |
|--------------------|--------|----|--------|--|
| Gross profit | 33.41% | -- | 35.49% | |
| Operating expenses | 27.85% | -- | 30.53% | |
| Operating income | 5.57% | -- | 4.96% | |

AmerisourceBergen

| | | | | |
|--------------------|-------|-------|-------|--|
| Corporation | | | | |
| Gross profit | 5.01% | 4.21% | 5.47% | |
| Operating expenses | 3.18% | 2.47% | 3.68% | |
| Operating income | 1.82% | 1.74% | 1.80% | |

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes merger costs.

AMERISOURCEBERGEN CORPORATION
EARNINGS PER SHARE

(In thousands, except per share data)
(unaudited)

Basic earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed on the basis of the weighted average number of shares of common stock outstanding during the period plus the dilutive effect of stock options.

Additionally, the diluted earnings per share calculation considers the convertible subordinated notes as if converted and, therefore, the effect of interest expense related to those notes is added back to net income in determining income available to common stockholders.

| | Three months ended | | Nine months ended | |
|--|--------------------|----------|-------------------|----------|
| | June 30, | June 30, | June 30, | June 30, |
| | 2002 | 2001 | 2002 | 2001 |
| Net income | \$90,224 | \$31,506 | \$249,981 | \$89,213 |
| Interest expense - convertible subordinated notes, net of income taxes | 2,481 | 2,513 | 7,442 | 5,599 |
| Income available to common stockholders | \$92,705 | \$34,019 | \$257,423 | \$94,812 |
| Weighted average common shares outstanding | 105,374 | 52,912 | 104,505 | 52,656 |
| Effect of dilutive securities: | | | | |
| Options to purchase common stock | 1,853 | 1,002 | 1,757 | 993 |
| Convertible subordinated notes | 5,664 | 5,664 | 5,664 | 4,170 |

Weighted average

| | | | | |
|---|---------|--------|---------|--------|
| common shares outstanding - diluted | 112,891 | 59,578 | 111,926 | 57,819 |
| | ===== | ===== | ===== | ===== |

Earnings per share:

| | | | | |
|---------|--------|--------|--------|--------|
| Basic | \$0.86 | \$0.60 | \$2.39 | \$1.69 |
| Diluted | \$0.82 | \$0.57 | \$2.30 | \$1.64 |

Appendix - A(1)

Pro Forma Information

The historical consolidated financial summary and summary segment information for the three-months and nine-months ended June 30, 2001, included in this press release, reflect only the results of AmeriSource Health Corporation, as predecessor to the Company. In order to enhance comparability, the following schedules as well as the summary segment information include fiscal 2001 financial data on a pro forma basis. Within these schedules, pro forma refers to the combined results of AmeriSource Health Corporation and Bergen Brunswig Corporation and are not intended to be consolidated financial statements of AmerisourceBergen prepared in accordance with generally accepted accounting principles and do not represent consolidated results as if the merger had occurred at the beginning of the periods presented. In addition, they are not necessarily indicative of the actual results which might have occurred had the operations and management of AmeriSource Health Corporation and Bergen Brunswig Corporation been combined at the beginning of fiscal 2001.

In addition, to enhance comparability of financial information between fiscal years, the pro forma information for fiscal 2001 excludes the amortization of goodwill and special items related to the merger and environmental remediation and reflects the full allocation of Bergen Brunswig Corporation's former Corporate segment to the Pharmaceutical Distribution and PharMerica segments.

Appendix - A(2)

AmerisourceBergen

Pro forma combined condensed financial information (1)
(dollars in thousands)

| | Fiscal Year Ended September 30, 2001 | | | | |
|---|--------------------------------------|-------------------|------------------|-------------------|----------------|
| | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Fiscal Year |
| Operating revenue | \$8,083,535 | \$8,467,976 | \$8,995,115 | \$9,052,684 | \$34,599,310 |
| Gross profit | \$442,249 | \$480,035 | \$475,810 | \$482,647 | \$1,880,741 |
| Distribution, selling and administrative (2) | 293,608 | 303,730 | 295,462 | 304,703 | 1,197,503 |
| Depreciation | 13,891 | 14,337 | 14,296 | 14,641 | 57,165 |
| Amortization (3) | 1,553 | 1,140 | 1,270 | 1,427 | 5,390 |
| Operating income | \$133,197 | \$160,828 | \$164,782 | \$161,876 | \$620,683 |
| Gross profit to operating revenue | 5.47% | 5.67% | 5.29% | 5.33% | 5.44% |
| Operating expenses to operating revenue | 3.82% | 3.77% | 3.46% | 3.54% | 3.64% |

income
to operating
revenue 1.65% 1.90% 1.83% 1.79% 1.79%

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes special items in the third and fourth quarters related to the merger and environmental remediation.

(3) Excludes amortization of goodwill.

Appendix - A(3)

AmerisourceBergen - Pharmaceutical Distribution
Pro forma combined condensed financial information (1)
(dollars in thousands)

Fiscal Year Ended September 30, 2001

First Second Third Fourth Fiscal Year
Quarter Quarter Quarter Quarter

Operating
revenue \$7,929,966 \$8,335,337 \$8,835,163 \$8,885,145 \$33,985,611
=====

Gross profit \$322,096 \$358,294 \$358,619 \$365,948 \$1,404,957

Distribution,
selling and
administrative

(2), (3) 195,464 202,915 200,042 211,501 809,922

Depreciation 9,426 9,962 9,916 10,278 39,582

Amortization (4) 1,116 703 835 972 3,626

Operating
income \$116,090 \$144,714 \$147,826 \$143,197 \$551,827
=====

Gross profit to
operating
revenue 4.06% 4.30% 4.06% 4.12% 4.13%

Operating
expenses to
operating
revenue 2.60% 2.56% 2.39% 2.51% 2.51%

Operating
income to
operating
revenue 1.46% 1.74% 1.67% 1.61% 1.62%

(1) Represents the combination of AmeriSource Health Corporation's and Bergen Brunswig Corporation's previously reported financial information. (See discussion under Pro Forma Information Appendix - A(1)).

(2) Excludes special items in the third and fourth quarters related to the merger and environmental remediation.

(3) Expenses previously reported in the Corporate segment for Bergen Brunswig Corporation have been fully allocated to the Pharmaceutical Distribution and PharMerica segments for comparative purposes within this schedule.

(4) Excludes amortization of goodwill.

Appendix - A(4)

AmerisourceBergen - PharMerica
Pro forma combined condensed financial information (1)
(dollars in thousands)

Fiscal Year Ended September 30, 2001

First Second Third Fourth Fiscal Year
Quarter Quarter Quarter Quarter

 Operating
 revenue \$335,166 \$339,924 \$336,783 \$338,135 \$1,350,008
 =====

Gross profit \$120,153 \$121,741 \$117,191 \$116,699 \$475,784

Distribution,
 selling and
 administrative

(2), (3) 98,144 100,815 95,420 93,202 387,581

Depreciation 4,465 4,375 4,380 4,363 17,583

Amortization (4) 437 437 435 455 1,764

Operating
 income \$17,107 \$16,114 \$16,956 \$18,679 \$68,856
 =====

Gross profit
 to operating

revenue 35.85% 35.81% 34.80% 34.51% 35.24%

Operating
 expenses to

operating
 revenue 30.74% 31.07% 29.76% 28.99% 30.14%

Operating
 income to

operating
 revenue 5.10% 4.74% 5.03% 5.52% 5.10%

(1) Represents the combination of AmeriSource Health Corporation's and
 Bergen Brunswig Corporation's previously reported financial
 information. (See discussion under Pro Forma Information Appendix
 - A(1)).

(2) Excludes special items in the third and fourth quarters related to
 the merger and enviromental remediation.

(3) Expenses previously reported in the Corporate segment for Bergen
 Brunswig Corporation have been fully allocated to the
 Pharmaceutical Distribution and PharMerica segments for
 comparative purposes within this schedule.

(4) Excludes amortization of goodwill.

Appendix - A(5)

AmerisourceBergen - Intersegment Eliminations

Pro forma combined condensed financial information (1)

(dollars in thousands)

Fiscal Year Ended September 30, 2001

 First Second Third Fourth Fiscal Year
 Quarter Quarter Quarter Quarter

Operating
 revenue (\$181,597) (\$207,285) (\$176,831) (\$170,596) (\$736,309)
 =====

Gross profit \$0 \$0 \$0 \$0 \$0

Distribution,
 selling and
 administrative

-- -- -- -- --

Depreciation -- -- -- -- --

Amortization -- -- -- -- --

Operating
 income \$0 \$0 \$0 \$0 \$0
 =====

(1) Represents the combination of AmeriSource Health Corporation's and
 Bergen Brunswig Corporation's previously reported financial
 information. (See discussion under Pro Forma Information Appendix
 - A(1)).

CONTACT: AmerisourceBergen
Michael N. Kilpatric, 610/727-7118
mkilpatric@amerisource.com